Angion Biomedica Company
Angion is a clinical stage biopharmaceutical company focused on acute kidney injury, a potentially life-threatening condition without therapeutic options. Our lead clinical asset, ANG-3777, is engineered to activate the HGF/c-MET pathway, an…
Technology:
Data-driven Technologies
Industry:
Small&Large Molecules
Headquarters:
New York, United States
Founded Date:
1998
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
2
Total Funding:
44356452
Estimated Revenue:
$10M to $50M
Last Funding Date:
2021
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership